Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis

Tuberculosis

Volumn 87, Issue 6, 2007, Pages 518-525

  Sugawara, I ^a   Li, Z ^b   Sun, L ^c   Udagawa, T ^a   Taniyama, T ^d  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

^b Shanghai H and G Biotechnology Co Inc   (China)

^c WUHAN UNIVERSITY   (China)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Ag85A; Cynomolgus monkey; H37Rv; Mycobacterium tuberculosis; Recombinant BCG

Indexed keywords

BCG VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; COLONY FORMING UNIT; CONTROLLED STUDY; GUINEA PIG; MACACA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULIN TEST;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BCG VACCINE; BLOOD SEDIMENTATION; LUNG; MACACA FASCICULARIS; MALE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; SPLEEN; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; VACCINES, DNA;

EID: 35348874800     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2007.06.002     Document Type: Article

References (24)

1. Clemens J.D., Chuong J.J., and Feinstein A.R. The BCG controversy. A methodological and statistical reappraisal. JAMA 249 (1983) 2362-2369
2. Zodpey S.P. The BCG controversy: a reappraisal of the protective effect against tuberculosis and leprosy. Indian J Public Health 48 (2004) 70-77
3. Haile M., and Kallenius G. Recent developments in tuberculosis vaccines. Curr Opin Infect Dis 18 (2005) 211-215
4. Andersen P., and Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3 (2005) 656-662
5. Sugawara I., Yamada H., Udarawa T., and Huygen K. Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment. Tuberculosis 83 (2003) 331-337
6. Sugawara I., Udagawa T., and Taniyama T. Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A. Tuberculosis 87 (2007) 94-101
7. Langermans J.A., Andersen P., van Soolingen D., Vervenne R.A., Frost P.A., vander Laan T., et al. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci USA 98 (2001) 11497-11502
8. Good R.C. Biology of the mycobacterioses Simian tuberculosis: immunologic aspects. Ann NY Acad Sci 154 (1968) 200-213
9. Ribi E., Anacker R.L., Barclay W.R., Brehmer W., Harris S.C., Leif W.R., et al. Efficacy of mycobacterial cell walls as a vaccine against airborne tuberculosis in the Rhesus monkey. J Infect Dis 123 (1971) 527-538
10. Walsh G.P., Tan E.V., dela Cruz E.C., Abalos R.M., Villahermosa L.G., Young L.J., et al. The Philippine cynomolgus monkey (Macaca fascicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 2 (1996) 430-436
11. Chambers M.A., Williamas A., Hatch G., Gavier-Widen D., Hall G., Huygen K., et al. Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis. Infect Immun 70 (2002) 2159-2165
12. Reed S., and Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect 7 (2005) 922-931
13. Dietrich J., Lundberg C.V., and Andersen P. TB vaccine strategies-what is needed to solve a complex problem?. Tuberculosis 86 (2006) 163-168
14. Skeiky Y.A., and Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4 (2006) 469-476
15. Kaufmann S.H., Baumann S., and Nasser Eddine A. Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int J Tuberc Lung Dis 10 (2006) 1068-1079
16. Horwitz M.A., Harth G., Dillon B.J., and Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 97 (2000) 13853-13858
17. Skeiky Y.A.W., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 (2004) 7618-7628
18. Brandt L., Skeiky Y.A., Alderson M.R., Lobet Y., Dalemans W., Turner O.C., et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72 (2004) 6622-6632
19. Guleria I., Teitelbaum R., McAdams R.A., Kaplan G., Jacobs Jr. W.R., and Bloom B.R. Auxotrophic vaccines for tuberculosis. Nat Med 2 (1996) 334-337
20. Langermans J.A.M., Doherty T.M., Vervenne R.A.W., van der Laan T., Lyashchenko K., Greenwald R., et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23 (2005) 2740-2750
21. Kita Y., Tanaka T., Yoshida S., Ohara N., Kaneda Y., Kuwayama S., et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 23 (2005) 2132-2135
22. Anderson A.B., and Brennan P. Proteins and antigens of Mycobacterium tuberculosis. In: Bloom B.R. (Ed). Tuberculosis. Pathogenesis, protection, and control (1994), ASM Press 307-332
23. Kamath A.T., Feng C.G., MacDonald M., Briscoe H., and Britton W.J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67 (1999) 1702-1707
24. Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M., Deck R.R., et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 2 (1996) 893-898